IVA Inventiva 6-K2021Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
5 Jan 21
Files
SEC
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
IVA 6-K Filings
- 5 Jan 21 Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
- 12 Nov 20 Current report (foreign)
- 10 Nov 20 Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH
- 5 Nov 20 Inventiva announces the appointment of Dr. Michael Cooreman as Chief Medical Officer
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…